![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 06, 2011 7:18:37 PM
La Jolla’s immediate plan is to conduct a confirmatory preclinical animal study of LJP1485 that it expects to complete by the end of the second quarter of 2011. If this study is successful, La Jolla will receive approximately $7.4 million upon the mandatory exercise of a portion of its outstanding preferred stock purchase warrants held by existing investors, and the investors will then forfeit their currently exercisable right to demand redemption of approximately $5.6 million of Series C Preferred Stock acquired in May 2010. The proceeds from this warrant exercise, combined with existing cash resources, are then expected to fund the Company’s operations through the completion of a Phase 2a proof-of-concept clinical study of LJP1485. If the Phase 2a study is successful, the balance of the preferred stock purchase warrants will be required to be exercised at that time, raising an additional $3.2 million.
News from April 2011.
Hard work never killed anybody, but why take a chance
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM